New intraocular lens containing a drug delivery system (IOL-DDS) loaded with dexamethasone

IF 3 4区医学 Q3 ENGINEERING, BIOMEDICAL

Biomedical Microdevices Pub Date : 2025-03-24 DOI:10.1007/s10544-025-00743-4

Brenda F. M. Castro, Raquel G. Arribada, Thomas T. Inoue, Elias R. Filho, Bruno C. Sena, Luiz F. L. Ferreira, Silvia L. Fialho, Armando Silva-Cunha

{"title":"New intraocular lens containing a drug delivery system (IOL-DDS) loaded with dexamethasone","authors":"Brenda F. M. Castro, Raquel G. Arribada, Thomas T. Inoue, Elias R. Filho, Bruno C. Sena, Luiz F. L. Ferreira, Silvia L. Fialho, Armando Silva-Cunha","doi":"10.1007/s10544-025-00743-4","DOIUrl":null,"url":null,"abstract":"<div><p>This study demonstrates the development of polymeric PLGA (50:50) nanoparticles containing dexamethasone acetate, which are dispersed in a PVA film and added to hydrophobic intraocular lenses (IOL) exclusively designed for this application. The resulting IOL-drug delivery system (IOL-DDS) can be introduced into the eye with syringe-type injectors and standard surgical techniques. The obtained results showed that the lens design does not compromise stability within the eye or weaken the loops, preserves its optical zone, and maintains injector’s functionality during surgery. The IOL-DDS releases the drug in vivo for 7 days within the therapeutic concentration range. Short-term assessment confirms the safety of the developed device for ocular structures, which is supported by slit lamp observations, intraocular pressure measurements, optical coherence tomography, and histological analysis. Minor changes in specular microscopy parameters are observed and may be related to the use of IOL and surgical instruments designed for human eyes in smaller rabbit eyes.</p></div>","PeriodicalId":490,"journal":{"name":"Biomedical Microdevices","volume":"27 2","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Microdevices","FirstCategoryId":"5","ListUrlMain":"https://link.springer.com/article/10.1007/s10544-025-00743-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

This study demonstrates the development of polymeric PLGA (50:50) nanoparticles containing dexamethasone acetate, which are dispersed in a PVA film and added to hydrophobic intraocular lenses (IOL) exclusively designed for this application. The resulting IOL-drug delivery system (IOL-DDS) can be introduced into the eye with syringe-type injectors and standard surgical techniques. The obtained results showed that the lens design does not compromise stability within the eye or weaken the loops, preserves its optical zone, and maintains injector’s functionality during surgery. The IOL-DDS releases the drug in vivo for 7 days within the therapeutic concentration range. Short-term assessment confirms the safety of the developed device for ocular structures, which is supported by slit lamp observations, intraocular pressure measurements, optical coherence tomography, and histological analysis. Minor changes in specular microscopy parameters are observed and may be related to the use of IOL and surgical instruments designed for human eyes in smaller rabbit eyes.

查看原文本刊更多论文

新型人工晶状体含有一种装载地塞米松的药物传递系统（IOL-DDS）

本研究展示了含有醋酸地塞米松的聚PLGA（50:50）纳米颗粒的发展，这些纳米颗粒分散在PVA薄膜中，并添加到专门为这种应用设计的疏水人工晶体（IOL）中。由此产生的IOL-DDS药物输送系统（IOL-DDS）可以通过注射器式注射器和标准手术技术引入眼睛。实验结果表明，该晶体设计不影响眼内稳定性，也不削弱环，保留其光学区，并在手术过程中保持注射器的功能。IOL-DDS在治疗浓度范围内体内释放药物7天。在裂隙灯观察、眼内压测量、光学相干断层扫描和组织学分析的支持下，短期评估证实了该设备用于眼部结构的安全性。在小兔子的眼睛中观察到镜面显微镜参数的微小变化，可能与人工晶体和为人眼设计的手术器械的使用有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomedical Microdevices 工程技术-工程：生物医学

CiteScore

6.90

自引率

3.60%

发文量

审稿时长

6 months

期刊介绍： Biomedical Microdevices: BioMEMS and Biomedical Nanotechnology is an interdisciplinary periodical devoted to all aspects of research in the medical diagnostic and therapeutic applications of Micro-Electro-Mechanical Systems (BioMEMS) and nanotechnology for medicine and biology. General subjects of interest include the design, characterization, testing, modeling and clinical validation of microfabricated systems, and their integration on-chip and in larger functional units. The specific interests of the Journal include systems for neural stimulation and recording, bioseparation technologies such as nanofilters and electrophoretic equipment, miniaturized analytic and DNA identification systems, biosensors, and micro/nanotechnologies for cell and tissue research, tissue engineering, cell transplantation, and the controlled release of drugs and biological molecules. Contributions reporting on fundamental and applied investigations of the material science, biochemistry, and physics of biomedical microdevices and nanotechnology are encouraged. A non-exhaustive list of fields of interest includes: nanoparticle synthesis, characterization, and validation of therapeutic or imaging efficacy in animal models; biocompatibility; biochemical modification of microfabricated devices, with reference to non-specific protein adsorption, and the active immobilization and patterning of proteins on micro/nanofabricated surfaces; the dynamics of fluids in micro-and-nano-fabricated channels; the electromechanical and structural response of micro/nanofabricated systems; the interactions of microdevices with cells and tissues, including biocompatibility and biodegradation studies; variations in the characteristics of the systems as a function of the micro/nanofabrication parameters.